drugset / Trial / NCT06194318

First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults

NCT06194318

Phase 1 Completed 160 enrolled Clover Biopharmaceuticals AUS Pty
RandomizedParallel-groupQuadruple-blindPrevention

Summary

First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults

Timeline

Start
2023-12-13
Primary completion
2025-02-26
Completion
2025-05-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Arexvy Vaccine
Subject SCB-1019 Vaccine
Subject SCB-1019T Vaccine